Header Logo

Connection

VIVEK SUBBIAH to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Lung Neoplasms.
VIVEK SUBBIAH
Connection Strength
4.889
Lung Neoplasms
  1. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types. Clin Cancer Res. 2024 02 16; 30(4):836-848.
    View in: PubMed
    Score: 0.196
  2. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases. Lung Cancer. 2024 02; 188:107448.
    View in: PubMed
    Score: 0.194
  3. Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases. Cancer. 2024 02 15; 130(4):530-540.
    View in: PubMed
    Score: 0.192
  4. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer Res. 2023 10 02; 83(19):3159-3161.
    View in: PubMed
    Score: 0.191
  5. Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours. Eur J Cancer. 2023 10; 192:113259.
    View in: PubMed
    Score: 0.189
  6. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. Am Soc Clin Oncol Educ Book. 2023 May; 43:e404770.
    View in: PubMed
    Score: 0.186
  7. Top advances of the year: Precision oncology. Cancer. 2023 06 01; 129(11):1634-1642.
    View in: PubMed
    Score: 0.184
  8. RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. Pharmacol Ther. 2023 02; 242:108344.
    View in: PubMed
    Score: 0.182
  9. Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment. JAMA Netw Open. 2022 11 01; 5(11):e2239874.
    View in: PubMed
    Score: 0.179
  10. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 10; 23(10):1261-1273.
    View in: PubMed
    Score: 0.178
  11. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nat Commun. 2022 06 17; 13(1):3500.
    View in: PubMed
    Score: 0.175
  12. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Mol Cancer Ther. 2022 06 01; 21(6):871-878.
    View in: PubMed
    Score: 0.174
  13. Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2022 05 02; 5(5):e2214046.
    View in: PubMed
    Score: 0.173
  14. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022 05; 33(5):522-533.
    View in: PubMed
    Score: 0.171
  15. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer. JAMA Netw Open. 2021 11 01; 4(11):e2134299.
    View in: PubMed
    Score: 0.167
  16. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Med. 2021 09 15; 19(1):209.
    View in: PubMed
    Score: 0.166
  17. Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 2021 12; 7(12):1074-1088.
    View in: PubMed
    Score: 0.165
  18. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res. 2021 08 01; 27(15):4160-4167.
    View in: PubMed
    Score: 0.163
  19. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819.
    View in: PubMed
    Score: 0.159
  20. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268.
    View in: PubMed
    Score: 0.156
  21. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020 12; 150:90-96.
    View in: PubMed
    Score: 0.155
  22. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824.
    View in: PubMed
    Score: 0.154
  23. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141.
    View in: PubMed
    Score: 0.131
  24. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer. 2015 Jul; 89(1):76-9.
    View in: PubMed
    Score: 0.106
  25. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet J Rare Dis. 2013 Jul 30; 8:112.
    View in: PubMed
    Score: 0.094
  26. To ring or wring the bell? J Palliat Med. 2011 Aug; 14(8):968-9.
    View in: PubMed
    Score: 0.082
  27. Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series. Clin Lung Cancer. 2023 11; 24(7):666-671.
    View in: PubMed
    Score: 0.047
  28. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat Rev Clin Oncol. 2023 10; 20(10):664-677.
    View in: PubMed
    Score: 0.047
  29. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2023 01 10; 41(2):385-394.
    View in: PubMed
    Score: 0.044
  30. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. JCO Precis Oncol. 2022 08; 6:e2200107.
    View in: PubMed
    Score: 0.044
  31. Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial. Oncologist. 2022 02 03; 27(1):22-29.
    View in: PubMed
    Score: 0.043
  32. 18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. Curr Probl Cancer. 2021 10; 45(5):100797.
    View in: PubMed
    Score: 0.042
  33. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 07; 22(7):959-969.
    View in: PubMed
    Score: 0.041
  34. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev. 2021 05; 96:102179.
    View in: PubMed
    Score: 0.040
  35. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
    View in: PubMed
    Score: 0.038
  36. RET Solvent Front Mutations Mediate Acquired?Resistance to Selective RET Inhibition in?RET-Driven Malignancies. J Thorac Oncol. 2020 04; 15(4):541-549.
    View in: PubMed
    Score: 0.037
  37. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
    View in: PubMed
    Score: 0.036
  38. Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. J Comput Assist Tomogr. 2018 May/Jun; 42(3):357-364.
    View in: PubMed
    Score: 0.033
  39. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 07; 8(7):836-849.
    View in: PubMed
    Score: 0.033
  40. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
    View in: PubMed
    Score: 0.029
  41. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol. 2014; 804:291-304.
    View in: PubMed
    Score: 0.024
  42. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol Cancer Ther. 2012 Nov; 11(11):2541-6.
    View in: PubMed
    Score: 0.022
  43. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009 Apr; 10(1-2):126-40.
    View in: PubMed
    Score: 0.018
  44. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015 Aug 20; 373(8):726-36.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.